

THE ANNALS OF PHARMACOTHERAPY

EDITORIAL OFFICE

Harvey Whitney Books Company
8044 Montgomery Rd., Ste. 415, Cincinnati, OH 45236-2919
PO Box 42696, Cincinnati, OH 45242-0696 USA
Telephone: 513/793-3555 FAX: 513/793-3600
theannals.com

AUTHOR GUIDELINES

Articles submitted for publication to *The Annals of Pharmacotherapy* should advance the safe, effective, and economical use of medications in patients.

Manuscript Submission

Submission should be made at theannals.com by clicking on "Author Information" and uploading the manuscript and cover letter in a format compatible with Microsoft Word for Windows. Combine title page, abstract, text, references, and table(s) into a single document prior to online submission. Art (eg, figures, photographs) must be computer-generated or scanned in high resolution (see also "Figures"). Each figure should be submitted as a separate electronic file. The Author Signature Form and other applicable documents (see "Other Considerations for Manuscript Submission") must be mailed to the Editorial Office within 10 days of manuscript submission. If online submission is not possible, a diskette or CD containing the cover letter, manuscript, and any figures must be mailed to the Editorial Office. Other applicable documents, as described above, must also be included.

Cover letter. All cover letters must include the following:

1. Name of corresponding author with full mailing address, telephone and fax numbers, and email address;
2. Article category preference (see "Article Categories");
3. Brief explanation of the topic's significance to patient care;
4. Explanation about any similar work by the author(s) or data from the same study that is under review or in press, or results previously presented or published (see "Duplicate Publication");
5. Request for anonymity during peer review, if desired (see also "Title Page");

Author Signature Form: The Author Signature form, containing Assignment of Copyright, Criteria for Authorship, and Acknowledgment, must be signed by each author and received by *The Annals* within 10 days of manuscript submission. Original signatures of all authors are required; faxed,

These Author Guidelines, as well as the Author Signature Form, can also be accessed directly from *The Annals'* Web site at theannals.com. In addition, copies are available from the Editorial Office.

photocopied, or scanned signatures are not acceptable. The form may be found at the end of these Author Guidelines, downloaded from theannals.com, or requested from the Editorial Office.

Assignment of Copyright: Authors must transfer all rights, title, and interest to their manuscript to Harvey Whitney Books Company, publisher of *The Annals of Pharmacotherapy*.

Criteria for Authorship: Authorship criteria are identical to those spelled out in the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals*. Specifically, authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. Assistance solely in nonsubstantive aspects of the submission, for example, the acquisition of funding, assembly of data, and referral of patients, does not justify authorship. At least one author must be responsible for each section of the manuscript.

Acknowledgment: Persons who have contributed significantly to the substance of the paper, but whose contributions do not justify authorship, should be acknowledged. Acknowledgment of technical writers must include their sources of funding. Authors must ensure that all persons named in the acknowledgment, excluding those providing financial or technical support, have agreed in writing to be named.

OTHER CONSIDERATIONS FOR MANUSCRIPT SUBMISSION

Permission to use copyrighted material: Written permission (original stamp/signature) from the publisher, organization, or person who holds copyright is necessary for use of previously published tables, figures, or other copyrighted material.

Informed consent: Identifying information should not be present in written descriptions or photographs of persons unless considered essential for scientific purposes. In such cases, written informed consent from the person must be obtained by the authors, with documentation included with manuscript submission.

Manuscript Checklist Form: This form, which can be found at the end of the Author Guidelines, must be completed and submitted within 10 days of manuscript submission.

Duplicate publication: Work that has been published or is described in an article submitted for publication elsewhere may not warrant further consideration. It is the corresponding author's responsibility to inform the editor about all submissions and previous reports describing the same work.

Rapid publication: If requested, justification of need should be provided.

Conflict of interest statement: Authors must report any conflicts of interest including, but not limited to, consulting fees, paid expert testimony, employment, grants, honoraria, patents, royalties, stocks, or other financial or material gain that may involve the subject matter of the manuscript. If there are no conflicts, authors should make a statement of this fact.

Article Categories

Expanded article category guidelines may be accessed from *The Annals* (theannals.com). Guidelines are also available from the Editorial Office.

Research Reports: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence and use, and pharmacy practice. Meta-analyses are also considered research. Well-designed prospective studies are given highest priority for acceptance. Limitations of studies must be stated in the text. All reports must include, when applicable, a statement in the Methods section that the work was conducted in compliance with Institutional Review Board/Human Subjects Research Committee requirements.

Review Articles: Comprehensive, significant, critical, and analytical reviews that include essential information on a well-delineated subject. Some articles are selected for *The Annals'* continuing education program (PharmaCE), for which the author provides a goal, objectives, and questions according to guidelines available from the Editorial Office. Reviews must synthesize and critically evaluate available data rather than simply describing the findings. Articles are classified using the subcategories below:

SPECIALTIES: Reviews within a specific clinical area (eg, cardiology, critical care, infectious diseases, oncology, pediatrics, psychiatry), drug interactions and reactions, and other areas such as pharmacoeconomics or pharmacoepidemiology.

DRUG INFORMATION ROUNDS: Answers to specific questions related to drug therapy that include recommendations based on available studies.

DRUG SELECTION PERSPECTIVES: Comparisons of drugs within a class or in different classes with the same indication(s).

FORMULARY FORUM: Comprehensive, comparative reviews of single drug entities to aid in the understanding of the merits of the agent relative to others in its class.

NEW DRUG APPROVALS: Brief reviews of single drug entities that have recently received FDA approval.

NEW DRUG DEVELOPMENTS: Reviews of single drug entities or classes of agents undergoing Phase 3 investigation with high potential for FDA approval within 2–3 years.

THERAPEUTIC CONTROVERSIES: Critical and balanced assessments of current problems or controversial issues in clinical therapeutics that provide recommendations based on literature and clinical experience.

THERAPEUTIC MONITORING: Reviews of drug therapy monitoring for purposes of optimizing treatment in individual patients or populations.

Case Reports: New or unusual events in one or more patients that expand the knowledge about common disease states or provide significant information about drug safety, adverse reactions, or interactions. Clinical and laboratory data and concurrent medications or diseases should be documented. Case reports describing adverse events should adhere to

the International Society for Pharmacoepidemiology and International Society of Pharmacovigilance's Guidelines for submitting adverse event reports for publication (Pharmacoepidemiol Drug Saf 2007;16:581-7. DOI 10.1002/pds.1399). Before submitting a report of an adverse drug reaction, the Naranjo ADR probability scale (Clin Pharmacol Ther 1981;30:239-45) or other validated and appropriate scale should be used to assess the likelihood that the events were drug-related. Likewise, for reports of drug interactions, the DIPS scale (Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423) or another validated scale should be applied. Ranking from the scale must be included in both abstract and text. Priority is given to cases for which the scores indicate a probable or definite association.

Special Contributions: Articles on unusual, topical, or historical subjects that are of unique interest or importance. Contact the Editorial Office prior to submission.

International Reports: Research, reviews, or reports on pharmacy practice and health care that are specific to countries other than the US.

Commentaries: Viewpoints on diverse, controversial, or topical subjects. Contact the Editorial Office prior to submission.

Letters and Comments: Letters and comments should address areas related to clinical practice, research, or education, including recently published articles. Letters are limited to no more than five authors. In cases where adverse effects or drug interactions are described, the Naranjo ADR probability scale or DIPS scale, respectively, should be used to determine the likelihood that the adverse effect was drug-related (see "Case Reports"). Comments must be submitted within 6 months of an article's publication.

Style Guidelines

Authors are required to follow *The Annals'* style, which is consistent with the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals* (www.icmje.org). Other useful style references are the *American Medical Association Manual of Style*; *Scientific Style and Format: The CBE Manual for Authors, Editors and Publishers*; and *The Chicago Manual of Style*.

Manuscript Preparation: Manuscripts should be prepared using a 12-point font (Times, not Times New Roman, is preferred) formatted for 8.5 x 11.0 inch (216 x 279 mm) paper (ISO A4 also acceptable), with margins of at least 1 inch (25 mm). All copy should be double-spaced, including title page, abstract, text, acknowledgments, references, tables, and figure legends. Pages must be numbered.

Title Page: The title page should contain:

1. Article title (concise, but indicating main focus of paper);
2. Name of each author as it should appear in print;
3. Highest academic degree, position title, and/or academic appointment of each author;
4. Names of departments and institutions with which each author is affiliated;
5. Name, address, telephone and fax numbers, and email address of corresponding author;

6. Name, address, fax number, and email address of author to whom reprint requests should be sent, if different from corresponding author;
7. Statement pertaining to funding and conflict of interest (see “Conflict of Interest Statement”);
8. Information about presentation of the work as an abstract or poster, if applicable;
9. Separate word counts of abstract and main text; and
10. Key words for purposes of indexing and searching.

Authors desiring anonymity during peer review must request this in the cover letter and provide a second copy of the manuscript with all identifying information removed and a title page with only items 1, 7, 8, 9, and 10.

Structured Abstract: Abstracts should be no more than 300 words. See the Author Information section on *The Annals’* Web site or abstracts in any recent issue of the journal for examples of proper abstract subheadings and content for each article category. Guidelines for the preparation of structured abstracts and examples of each are available from theannals.com or the Editorial Office. Commentaries require an unstructured abstract of not more than 100 words. Reference citations are not used in the abstract.

Text: Appropriate headings and subheadings should be used liberally throughout the text. Abbreviations must be defined upon first use in the text. Use of abbreviations should be limited to, for example, lengthy terms; the majority of drug names should not be abbreviated. USANs or, when appropriate, chemical names, must be used for all drugs. Manufacturers’ code numbers should be used only when a generic name is not yet available. Trade names should be included only to distinguish between different trade preparations, for some combination drugs, or in reviews of drugs that have been recently approved by the FDA.

References: All references, including those related primarily to figures and tables, must appear in the text and be cited consecutively. References in text, tables, and figure legends should be denoted with superscript Arabic numerals.

Personal communications (ie, unpublished data) may not be used as numbered references. Information obtained through personal communication must be inserted in parentheses within the text and include the contact person’s name, academic degree, affiliation, and date of communication. Signed permission letters from quoted sources indicating the content of the personal communication must be provided to the Editorial Office.

Abstracts and Letters to the Editor may be used as numbered references but must be identified as such in the citations. Inclusive pagination must be provided for all references. Journal names should be abbreviated as they appear in PubMed. Those not appearing in PubMed should be spelled out. Referenced articles that are cited as “In press” must include the title of the journal that has accepted the paper.

List all authors when there are 6 or fewer; with 7 or more authors, list the first 3, followed by et al.

To facilitate online retrieval of references, include a citation’s digital object identifier (DOI) if available. More infor-

mation about DOIs can be obtained at www.crossref.org or dx.doi.org. When citing articles that have been published online prior to print, authors are encouraged to include the date published online (Epub date) in addition to the full print information. Examples of correct referencing style are given below.

ARTICLE

Baldwin DS, Heldbo Reines E, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. *Ann Pharmacother* 2007;41:1583-92. Epub 11 Sept 2007. DOI 10.1345/aph.1K089

ARTICLE WITH URL

Centers for Disease Control and Prevention. Strongyloidiasis. www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm (accessed 2007 Aug 17).

ABSTRACT

Rao N, Knebel W, Bergsma T, et al. Population pharmacokinetics of istradefylline (abstract 13). *J Clin Pharmacol* 2007;47:1185.

JOURNAL SUPPLEMENT

Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation executive summary: Joint American College of Chest Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation Evidence-Based Clinical Practice Guidelines. *Chest* 2007;131(suppl):1S-3S. DOI 10.1378/chest.07-0892

JOURNAL OR MAGAZINE PAGINATED BY ISSUE

Vyzral K. Legislative update. *Ohio Pharmacist* 2007;56(9):17.

BOOK CHAPTER

Shah M, Cunningham MJ. Toxicogenomics. In: Gad SC, ed. *Handbook of pharmaceutical biotechnology*. 1st ed. Hoboken, NJ: John Wiley & Sons, Inc., 2007:229-51.

PACKAGE INSERT

Product information. Zantac (ranitidine). Research Triangle Park, NC: GlaxoSmithKline, June 2007.

SCIENTIFIC PRESENTATION

Davis TM, Yeap B, Bruce DG, Davis WA. Lipid-lowering therapy protects against peripheral sensory neuropathy in type 2 diabetes. Presented at: 67th Scientific Sessions. American Diabetes Association Annual Meeting, 2007.

MONOGRAPH IN ELECTRONIC FORMAT

Tamoxifen. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, expires 2007 Dec 31 (accessed 2007 Jan 11).

Appendices: When necessary, appendices should be used to present lengthy or detailed surveys, descriptions of extensive mathematical calculations, and/or itemized lists. They should be placed (with legends as needed) following the reference list in the manuscript. Lengthy appendices, such as algorithms, surveys, and protocols, will be published only online; the URL will be provided in the printed article where the appendix is cited.

Tables: Each table must be double-spaced on a separate page. A brief title must be provided for each table. Each column requires a brief descriptive heading. Explanations and full terms for abbreviations used should appear alphabetically below the body of table. Statistical measures of variation (ie, standard deviation) should be identified in footnotes (designated as a, b, c, etc.). The units of measure used for all data in a column

should be indicated. Internal horizontal or vertical rules should not be used. Duplication of table content within text should be minimized.

Figures: Figures should be computer generated, photographed, or professionally drawn and submitted in TIFF format (photographs 300 dpi; line art 1200 dpi). Original hard copies or electronic files are required; photocopies are not acceptable. Each figure should be provided as a separate page or electronic file. Figures generated in PowerPoint, as well as freehand or with typewritten lettering, are unacceptable. Send an electronic version of each figure or 2 sharp, glossy originals of photographs; sharp laser copies of line art are acceptable. Letters, numbers, and symbols should be clear, uniform in size, and large and dark enough to be legible when the size of the figure is reduced to fit column width in the journal. Ti-

tles and detailed explanations should appear in the legends rather than in the figures.

Bar graphs or pie charts should be in black and white only and not contain gray shading as filler or background; distinctive fillings should be used instead (eg, white or solid black; horizontal, vertical, or slanted stripes; cross-hatching; dots). Dotted lines and decimal points should be dark enough to reproduce well. Background horizontal or vertical lines should not be used. Figures should have labels on their margins or backs indicating file number, figure number, and corresponding author's name at top of figure. The top of a figure should also be designated on the back if the figure lacks distinguishing features. Legends should be double-spaced, and each abbreviation and symbol used must be defined. Duplication of figure content within text should be minimized.

THE ANNALS OF PHARMACOTHERAPY

MANUSCRIPT CHECKLIST

Please complete and return this checklist with your other submission materials. It is important that each item be addressed.

I have checked the following items to confirm that they have been included with my submission packet and/or have been given consideration:

Required Items For All Submissions

- 1. Cover letter containing all required information, including preference for appropriate Article Category
- 2. Title page containing all required information, including
 - a. concise title
 - b. conflict of interest statement and funding information
- 3. Electronic manuscript file
- 4. Electronic files of any figures or tables; figures submitted in high resolution in TIFF format
- 5. *Separate* Author Signature Form signed by *each* author

Required Items, If Applicable

- 1. Clear, camera-ready (glossies or 300 dpi computer-generated for photographs; 1200 dpi for line art) copy of figures
- 2. Permission to publish material from another source
- 3. Informed consent for use of identifiable descriptions or photographs of persons
- 4. Institutional Review Board/Human Subjects Research Committee approval

Other Items For Consideration

- 1. Separate abstract and word counts and key words indicated on title page
- 2. Manuscript conforms to specific Article Category guidelines
- 3. Structured abstract included, with proper abstract subheadings for particular article category
- 4. All copy is double-spaced and in 12-point font (Times, not Times New Roman, is preferred), with pages numbered
- 5. All abbreviations are defined unless they are standard units of measurement
- 6. Results of the Naranjo, DIPS, or other validated and appropriate scale are included for case reports and letters when adverse drug reactions or drug interactions are being reported
- 7. Tables are double-spaced and on separate pages
- 8. References have been checked for accuracy and style

Corresponding Author's Initials

**HARVEY WHITNEY BOOKS COMPANY
AUTHOR SIGNATURE FORM**

(use one form per author)

INSTRUCTIONS: *Each author must complete and sign a separate copy of this form. All authors must sign either line A or B (whichever is applicable). All authors must also sign line C. Only the corresponding author must sign line D. Mail all copies to: Harvey Whitney Books Company, PO Box 42696, Cincinnati, OH 45242-0696. Only forms with original signatures are acceptable (no faxed, photocopied, or electronic signatures).*

ASSIGNMENT OF COPYRIGHT

Authors are required to transfer all rights, title, and interest to their manuscripts, including copyright, to Harvey Whitney Books Company. The Copyright Act of 1976 states that the signature of every author must be present to effect the transfer. A manuscript cannot be considered for publication until the original signature of each author is on file in the Editorial Office.

As a consideration of the expense incurred by Harvey Whitney Books Company in undertaking reviewing, editing, and publishing the article identified below,

(insert article title): _____

the undersigned author hereby transfers, assigns, or otherwise conveys to Harvey Whitney Books Company:

- (1) all copyright ownership in all print and electronic formats;
- (2) the right to grant permission to republish or reprint the stated material, in whole or in part, with or without a fee;
- (3) the right to print copies for free distribution or sale; and
- (4) the right to republish the stated material in any format.

In addition, the undersigned affirms that the article or other written work described above has not been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Harvey Whitney Books Company with this document.

A _____
Author's name (printed) Author's signature (do not use "per" signature) Date

-or- I was a US federal employee when this work was done and prepared for publication. This work is not protected by the Copyright Act and ownership cannot be transferred.

B _____
Author's name (printed) Author's signature (do not use "per" signature) Date

CRITERIA FOR AUTHORSHIP

I hereby certify that I have made a substantial contribution to this manuscript in: (1) conception and design, or acquisition of data, or analysis, and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors must meet conditions 1, 2, and 3.

C _____
Author's name (printed) Author's signature (do not use "per" signature) Date

ACKNOWLEDGMENT

All persons who have made substantial contributions to the preparation of the manuscript, but who are not authors, are named in the Acknowledgment section and have agreed in writing to be named. No contributor has been omitted.

D _____
Corresponding author's signature Date